Procedure for predicting progressing hepatic fibrosis in patients with human immunodeficiency and hepatitis C coinfection

Our research goal was to develop a system for predicting nature of fibrosis processes in patients infected with HIV and Hepatitis C virus and to assess its efficiency bearing in mind peculiarities of anti-virus therapy applied for treating the infections. Research was performed on 459 patients with confirmed HIV/viral hepatitis C who had been treated for 1 year at Saratov Regional Center for AIDS Prevention and Elimination. Most patients were males younger than 36. 72-78 % patients had 3-4A HIV infection stages. The rest had 4B-C stages. 32 % were treated only with sets of anti-retroviruses medications made up of nucleoside and non-nucleoside inhibitors of reverse transcriptase, inhibitors of protease, and inhibitors of integrase in different combinations. 14 % patients infected with both HIV and Hepatitis C virus were treated only with antiviral medications aimed for treating hepatitis C and made up of pegylated interferon α and ribavirin or medications with direct effects such as sofosbuvir and daclatasvir...